Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ (2010) Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 11 (3): 266–274
Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D . Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. Plos Med (2010) 7 (5): e1000279, pages 1–12
Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304 (1): 10–15
Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 274 (10): 796–797
Bonadonna G, Zambetti M, Moliterni A, Gianni L, Valagussa P (2004) Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. J Clin Oncol 22 (9): 1614–1620
Buzzoni R, Bonadonna G, Valagussa P, Zambetti M (1991) Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9 (12): 2134–2140
Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, Hiller L, Dunn J, Hopwood P, Barrett-Lee P, Ellis P, Cameron D, Harris AL, Gray AM, Sculpher M (2011) The cost-effectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur J Cancer 47 (17): 2517–2530
Coombes RC, Bliss JM, Wils J, Morvan F, Espié M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Pérez-López FR, Vassilopoulos P, Ferreira EP, Chilvers CE, Coombes G, Woods EM, Marty M (1996) Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 14 (1): 35–45
Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M HER2/TOP2A Meta-analysis Study Group (2011) Meta-analysis of HER-2 and Topoisomerase IIα as predictive biomarkers for anthracycline benefit: definitive individual patient data analysis from five randomised clinical trials of CMF versus anthracycline-based adjuvant therapy in early breast cancer. Lancet Oncol 12 (12): 1134–1142
Earl HM, Iddawela M (2004) Epirubicin as adjuvant breast cancer treatment. Expert Rev Anticancer Therapy 4 (2): 189–195
Earl HM, Hiller L, Dunn JA, Bathers S, Harvey P, Stanley A, Grieve RJ, Agrawal RK, Fernando IN, Brunt AM, McAdam K, O'Reilly S, Rea DW, Spooner D, Poole CJ NEAT Investigators (2008) NEAT: National Epirubicin Adjuvant Trial-Toxicity, Delivered Dose Intensity and Quality of Life. Br J Cancer 99 (8): 1226–1231
Early Breast Cancer Trialists’ Collaborative Group (1990) Treatment of Early Breast Cancer Vol 1 Worldwide evidence 1985-1990, Oxford University Press: Oxford, England
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic therapy of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences, and 24,000 deaths among 75,000 women. Lancet 339: 71–85
Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717
Engelsman E, Klijn JC, Rubens RD, Wildiers J, Beex LV, Nooij MA, Rotmensz N, Sylvester R (1991) ‘Classical’ CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer 27 (8): 966–970
Goldie JH, Coldman AJ, Gudauskas GA (1982) 1 Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66 (3): 439–449
Habeshaw T, Paul J, Jones R, Stallard S, Stewart M, Kaye SB, Soukop M, Symonds RP, Reed NS, Rankin EM (1991) Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomised trial. J Clin Oncol 9: 295–304
Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM (1998) Time-dependence of hazard ratios of prognostic factors in primary breast cancer. Breast Cancer Res Treat 52: 227–237
Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1998) Randomised trial of intensive cyclophosphamide, epirubicin, and fluorouracil compared with cyclophosphamide, methotrexate and fluorouracil in pre-menopausal women with node-positive breast cancer. J Clin Oncol 16: 2651–2658
Moliterni A, Bonadonna G, Valagussa P, Ferrari L, Zambetti M (1991) Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9 (7): 1124–1130
Norton L, Day R (1991) Potential innovations in scheduling of cancer chemotherapy. Important Adv Oncol 57–72
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human tumours. Nature 406 (6797): 747–752
Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ NEAT Investigators and the SCTBG (2006) Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. N Engl J Med 355: 1851–1862
Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D (2005) Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23 (18): 4179–4191
Rea DW, Hiller L, Earl HM, Dunn JA, Bathers S, Spooner D, Grieve R, Agrawal RK, Poole CJ on behalf of the NEAT Investigators (2004) Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: a non-randomised comparison of patients treated in the National Epirubicin Adjuvant trials (NEAT). J Clin Oncol 22, 14(s): abstract 595